Show simple item record

dc.contributor.authorAl-Ani, Enas
dc.contributor.authorHeaselgrave, Wayne
dc.date.accessioned2022-01-19T14:42:39Z
dc.date.available2022-01-19T14:42:39Z
dc.date.issued2022-01-05
dc.identifier.citationAl-Ani, E. and Heaselgrave, W. (2022) The Investigation of Thymol Formulations Containing Poloxamer 407 and Hydroxypropyl Methylcellulose to Inhibit Candida Biofilm Formation and Demonstrate Improved Bio-Compatibility. Pharmaceuticals. 2022; 15(1):71. https://doi.org/10.3390/ph15010071en
dc.identifier.issn1424-8247en
dc.identifier.doi10.3390/ph15010071en
dc.identifier.urihttp://hdl.handle.net/2436/624553
dc.description© 2022 The Authors. Published by MDPI. This is an open access article available under a Creative Commons licence. The published version can be accessed at the following link on the publisher’s website: https://doi.org/10.3390/ph15010071en
dc.description.abstractThe aim of this study was to investigate the potential of thymol to inhibit Candida biofilm formation and improve thymol biocompatibility in the presence of hydroxypropyl methylcellulose (HPMC) and poloxamer 407 (P407), as possible drug carriers. Thymol with and without polymers were tested for its ability to inhibit biofilm formation, its effect on the viability of biofilm and biocompatibility studies were performed on HEK 293 (human embryonic kidney) cells. Thymol showed a concentration dependent biofilm inhibition; this effect was slightly improved when it was combined with HPMC. The Thymol-P407 combination completely inhibited the formation of biofilm and the antibiofilm effect of thymol decreased as the maturation of Candida biofilms increased. The effect of thymol on HEK 293 cells was a loss of nearly 100% in their viability at a concentration of 250 mg/L. However, in the presence of P407, the viability was 25% and 85% using neutral red uptake and sulforhodamine B assays, respectively. While, HPMC had less effect on thymol activity the thymol-P407 combination showed a superior inhibitory effect on biofilm formation and better biocompatibility with human cell lines. The combination demonstrates a potential medical use for the prevention of Candida biofilm formation.en
dc.formatapplication/pdfen
dc.languageen
dc.language.isoenen
dc.publisherMDPIen
dc.relation.urlhttps://www.mdpi.com/1424-8247/15/1/71en
dc.subjectthymolen
dc.subjecthydroxypropyl methyl celluloseen
dc.subjectpoloxamer 407en
dc.subjectCandida albicansen
dc.subjectbiofilm inhibitionen
dc.subjectantibiofilmen
dc.subjectbiocompatibilityen
dc.titleThe investigation of thymol formulations containing poloxamer 407 and hydroxypropyl methylcellulose to inhibit candida biofilm formation and demonstrate improved bio-compatibilityen
dc.typeJournal articleen
dc.identifier.eissn1424-8247
dc.identifier.journalPharmaceuticalsen
dc.date.updated2022-01-18T18:51:53Z
dc.date.accepted2021-12-31
rioxxterms.funderUniversity of Wolverhamptonen
rioxxterms.identifier.projectUOW19012022EAen
rioxxterms.versionVoRen
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0/en
rioxxterms.licenseref.startdate2022-10-19en
dc.source.volume15
dc.source.issue1
dc.source.beginpage71
dc.source.endpage71
dc.description.versionPublished online
refterms.dateFCD2022-01-19T14:41:33Z
refterms.versionFCDVoR
refterms.dateFOA2022-01-19T14:42:40Z


Files in this item

Thumbnail
Name:
pharmaceuticals-15-00071.pdf
Size:
6.654Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/